133 related articles for article (PubMed ID: 12810621)
21. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden.
Le Gall C; Bellahcène A; Bonnelye E; Gasser JA; Castronovo V; Green J; Zimmermann J; Clézardin P
Cancer Res; 2007 Oct; 67(20):9894-902. PubMed ID: 17942921
[TBL] [Abstract][Full Text] [Related]
22. [The role of bisphosphonates of adjuvant therapy in breast cancer].
Gálvez-Muñoz E; Rodríguez-Lescure Á
Med Clin (Barc); 2010 Jun; 135(2):70-4. PubMed ID: 20022069
[TBL] [Abstract][Full Text] [Related]
23. Site-specific human breast cancer (MDA-MB-231) metastases in nude rats: model characterisation and in vivo effects of ibandronate on tumour growth.
Neudert M; Fischer C; Krempien B; Bauss F; Seibel MJ
Int J Cancer; 2003 Nov; 107(3):468-77. PubMed ID: 14506749
[TBL] [Abstract][Full Text] [Related]
24. A synthetic antagonist to laminin inhibits the formation of osteolytic metastases by human melanoma cells in nude mice.
Nakai M; Mundy GR; Williams PJ; Boyce B; Yoneda T
Cancer Res; 1992 Oct; 52(19):5395-9. PubMed ID: 1394144
[TBL] [Abstract][Full Text] [Related]
25. RANK ligand is a prerequisite for cancer-associated osteolytic lesions.
Kitazawa S; Kitazawa R
J Pathol; 2002 Oct; 198(2):228-36. PubMed ID: 12237883
[TBL] [Abstract][Full Text] [Related]
26. [Role of diphosphonates in the therapy of osteolysis and malignant hypercalcemia].
Delmas PD; Charhon SA; Chapuy MC; Meunier PJ
Rev Rhum Mal Osteoartic; 1984 Dec; 51(11):663-6. PubMed ID: 6523018
[No Abstract] [Full Text] [Related]
27. Targeting the alphavbeta3 integrin for small-animal PET/CT of osteolytic bone metastases.
Wadas TJ; Deng H; Sprague JE; Zheleznyak A; Weilbaecher KN; Anderson CJ
J Nucl Med; 2009 Nov; 50(11):1873-80. PubMed ID: 19875645
[TBL] [Abstract][Full Text] [Related]
28. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo.
Hughes DE; Wright KR; Uy HL; Sasaki A; Yoneda T; Roodman GD; Mundy GR; Boyce BF
J Bone Miner Res; 1995 Oct; 10(10):1478-87. PubMed ID: 8686503
[TBL] [Abstract][Full Text] [Related]
29. Rapamycin inhibits osteolysis and improves survival in a model of experimental bone metastases.
Hussein O; Tiedemann K; Murshed M; Komarova SV
Cancer Lett; 2012 Jan; 314(2):176-84. PubMed ID: 22014409
[TBL] [Abstract][Full Text] [Related]
30. Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice.
Clohisy DR; Ramnaraine ML; Scully S; Qi M; Van G; Tan HL; Lacey DL
J Orthop Res; 2000 Nov; 18(6):967-76. PubMed ID: 11192258
[TBL] [Abstract][Full Text] [Related]
31. Intravenous ibandronate rapidly reduces pain, neurochemical indices of central sensitization, tumor burden, and skeletal destruction in a mouse model of bone cancer.
Halvorson KG; Sevcik MA; Ghilardi JR; Sullivan LJ; Koewler NJ; Bauss F; Mantyh PW
J Pain Symptom Manage; 2008 Sep; 36(3):289-303. PubMed ID: 18411018
[TBL] [Abstract][Full Text] [Related]
32. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis.
Guise TA; Yin JJ; Taylor SD; Kumagai Y; Dallas M; Boyce BF; Yoneda T; Mundy GR
J Clin Invest; 1996 Oct; 98(7):1544-9. PubMed ID: 8833902
[TBL] [Abstract][Full Text] [Related]
33. Bone marrow mesenchymal stem cells provide an alternate pathway of osteoclast activation and bone destruction by cancer cells.
Sohara Y; Shimada H; Minkin C; Erdreich-Epstein A; Nolta JA; DeClerck YA
Cancer Res; 2005 Feb; 65(4):1129-35. PubMed ID: 15734993
[TBL] [Abstract][Full Text] [Related]
34. Antitumor effects of bisphosphonates.
Green JR
Cancer; 2003 Feb; 97(3 Suppl):840-7. PubMed ID: 12548584
[TBL] [Abstract][Full Text] [Related]
35. Response of MBT-2 bladder carcinoma-induced osteolysis to various agents.
Nemoto R; Satou S; Mochizuki T; Okabe K
Cancer; 1992 May; 69(9):2316-21. PubMed ID: 1562978
[TBL] [Abstract][Full Text] [Related]
36. The bisphosphonate YM529 inhibits osteoblastic bone tumor proliferation of prostate cancer.
Yonou H; Ochiai A; Ashimine S; Maeda H; Horiguchi Y; Yoshioka K; Ogawa Y; Hatano T; Tachibana M
Prostate; 2007 Jun; 67(9):999-1009. PubMed ID: 17440967
[TBL] [Abstract][Full Text] [Related]
37. Combination with third-generation bisphosphonate (YM529) and interferon-alpha can inhibit the progression of established bone renal cell carcinoma.
Kurabayashi A; Inoue K; Fukuhara H; Karashima T; Fukata S; Kawada C; Shuin T; Furihata M
Cancer Sci; 2015 Aug; 106(8):1092-9. PubMed ID: 26041278
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms and treatment for bone metastases.
Clines GA; Guise TA
Clin Adv Hematol Oncol; 2004 May; 2(5):295-302. PubMed ID: 16163196
[TBL] [Abstract][Full Text] [Related]
39. Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines.
Ono K; Akatsu T; Murakami T; Kitamura R; Yamamoto M; Shinomiya N; Rokutanda M; Sasaki T; Amizuka N; Ozawa H; Nagata N; Kugai N
J Bone Miner Res; 2002 May; 17(5):774-81. PubMed ID: 12009007
[TBL] [Abstract][Full Text] [Related]
40. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma.
Yoneda T; Michigami T; Yi B; Williams PJ; Niewolna M; Hiraga T
Cancer; 2000 Jun; 88(12 Suppl):2979-88. PubMed ID: 10898341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
